Indications for Bi-V AICD
A biventricular implantable cardioverter-defibrillator (Bi-V AICD or CRT-D) is indicated when a patient meets BOTH standard ICD criteria AND cardiac resynchronization therapy (CRT) criteria—specifically: heart failure with LVEF ≤35%, NYHA class II-III symptoms despite optimal medical therapy for ≥3-6 months, and QRS duration ≥120 ms (preferably ≥150 ms), with expected meaningful survival >1 year. 1, 2
Core Indication Framework
The decision for Bi-V AICD requires meeting two separate sets of criteria simultaneously:
1. ICD Component Indications 1
Primary Prevention:
- Ischemic cardiomyopathy with LVEF ≤30%, measured ≥40 days post-MI and ≥3 months post-revascularization, NYHA class II-III
- Non-ischemic dilated cardiomyopathy with LVEF ≤35%, present for ≥3 months on optimal medical therapy, NYHA class II-III
Secondary Prevention:
- Prior cardiac arrest from VF or hemodynamically unstable VT without reversible cause
- Sustained VT with structural heart disease
2. CRT Component Indications 2
Required criteria:
- LVEF ≤35% despite ≥6 weeks of optimal heart failure therapy
- NYHA class III symptoms (or class II with LVEF ≤30%)
- QRS duration >120 ms (strongest benefit when ≥150 ms)
- Sinus rhythm (relative requirement—benefit less clear in atrial fibrillation)
Additional dyssynchrony markers strengthen indication when QRS 120-149 ms: 3
- Aortic pre-ejection delay >140 ms
- Interventricular mechanical delay >40 ms
- Delayed posterolateral LV wall activation
Clinical Decision Algorithm
Step 1: Confirm ICD indication exists (primary or secondary prevention criteria above)
Step 2: Assess for CRT criteria:
- Is LVEF ≤35%?
- Is patient NYHA class II-III despite optimal medical therapy for ≥3-6 months?
- Is QRS ≥120 ms?
Step 3: If all criteria met → Choose CRT-D over CRT-P or ICD alone 2
Critical Nuances
CRT-D vs CRT-P Decision: The 2013 ESC guidelines acknowledge that trial evidence doesn't definitively prove CRT-D superiority over CRT-P, but the prevailing expert consensus favors CRT-D for incremental survival benefit and sudden death prevention 2. The guidelines note this is a IIa recommendation (Level B evidence), meaning CRT-D "should be considered" rather than being an absolute mandate.
Practical considerations favoring CRT-P over CRT-D: 2
- Advanced age (>70 years)
- Multiple comorbidities limiting survival <18 months
- End-stage heart failure (NYHA class IV) where quality of life improvement is primary goal
- Higher complication risk tolerance concerns
- Cost constraints
Common Pitfalls to Avoid:
Timing errors: Don't implant too early post-MI (<40 days) or post-revascularization (<3 months)—many patients improve with medical therapy alone 1
Inadequate medical optimization: Ensure ≥3-6 months of guideline-directed medical therapy at maximally tolerated doses before device consideration 1, 3
Ignoring meaningful survival requirement: All ICD recommendations require expected survival >1 year with reasonable quality of life and functional status 1
QRS duration threshold: While 120 ms is the minimum, benefit is substantially greater with QRS ≥150 ms, particularly with left bundle branch block morphology
Special Population—Prior Cardiac Arrest with LBBB: These patients represent the "optimal candidates" for combined therapy, as they have clear indications for both components 4
Prevalence in ICD populations: Approximately 10-20% of patients receiving ICDs meet criteria for biventricular pacing at implant, with an additional 6% developing indications during follow-up 5, 6